We are live on
!
Find out more
SEC
Seven Eight Capital Portfolio holdings
AUM
$1.11B
1-Year Est. Return
29.48%
This Fund
S&P 500
This Quarter
Est. Return
-6.56%
1 Year Est. Return
+29.48%
3 Year Est. Return
+13.61%
5 Year Est. Return
+117.69%
10 Year Est. Return
+239.1%
AUM
$855M
AUM Growth
+$250M
(+41%)
Cap. Flow
+$327M
Cap. Flow
% of AUM
38.29%
Top 10 Holdings %
Top 10 Hldgs %
13.1%
Holding
788
New
316
Increased
155
Reduced
106
Closed
211
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edwards Lifesciences
EW
|
+$13.6M |
| 2 |
Merck
MRK
|
+$12.5M |
| 3 |
Intuitive Surgical
ISRG
|
+$11.1M |
| 4 |
DOCU
DocuSign
DOCU
|
+$10.9M |
| 5 |
Insulet
PODD
|
+$10.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nasdaq
NDAQ
|
+$7.26M |
| 2 |
BioMarin Pharmaceuticals
BMRN
|
+$6.86M |
| 3 |
Incyte
INCY
|
+$6.31M |
| 4 |
Fidelity National Information Services
FIS
|
+$5.73M |
| 5 |
AbbVie
ABBV
|
+$4.95M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.41% |
| 2 | Consumer Discretionary | 17.68% |
| 3 | Healthcare | 16.13% |
| 4 | Industrials | 12.13% |
| 5 | Financials | 8.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
401
Kulicke & Soffa
KLIC
$4.91B
| $469K | 0.05% |
9,642
-117
| -1% | -$6.2K |
|
402
Baker Hughes
BKR
$60.4B
| $469K | 0.05% |
+13,273
| New | +$470K |
|
403
Moog Inc Class A
MOG.A
$12.5B
| $467K | 0.05% |
+4,138
| New | +$464K |
|
404
Stride
LRN
$3.41B
| $466K | 0.05% |
+10,359
| New | +$421K |
|
|
ARCH
405
DELISTED
Arch Resources, Inc.
ARCH
| $466K | 0.05% |
+2,732
| New | +$366K |
|
|
JHG
406
DELISTED
Janus Henderson
JHG
| $465K | 0.05% |
+18,007
| New | +$492K |
|
407
Marathon Petroleum
MPC
$89.6B
| $464K | 0.05% |
3,068
-8,034
| -72% | -$1.12M |
|
|
ANSS
408
DELISTED
Ansys
ANSS
| $463K | 0.05% |
+1,557
| New | +$493K |
|
409
Synopsys
SNPS
$75.1B
| $460K | 0.05% |
1,003
-543
| -35% | -$243K |
|
410
Chemours
CC
$2.57B
| $460K | 0.05% |
+16,407
| New | +$563K |
|
411
Allison Transmission
ALSN
$10.2B
| $460K | 0.05% |
7,788
+1,155
| +17% | +$68K |
|
412
Marqeta
MQ
$1.88B
| $459K | 0.05% |
+19,175
| New | +$435K |
|
|
RYZ
413
Ryerson Holding Corp
RYZ
$1.46B
| $449K | 0.05% |
+15,447
| New | +$524K |
|
414
Cirrus Logic
CRUS
$6.42B
| $448K | 0.05% |
6,061
-1,187
| -16% | -$92.7K |
|
415
Vista Energy
VIST
$7.5B
| $448K | 0.05% |
+14,744
| New | +$386K |
|
416
Nu Holdings
NU
$69.8B
| $448K | 0.05% |
61,779
-70,610
| -53% | -$528K |
|
417
Hartford Financial Services
HIG
$38.9B
| $447K | 0.05% |
+6,309
| New | +$458K |
|
418
Halliburton
HAL
$26.6B
| $444K | 0.05% |
+10,973
| New | +$430K |
|
419
Lincoln National
LNC
$8.82B
| $444K | 0.05% |
+17,967
| New | +$470K |
|
420
Invesco
IVZ
$13.6B
| $438K | 0.05% |
+30,133
| New | +$485K |
|
|
K
421
DELISTED
Kellanova
K
| $437K | 0.05% |
8,335
-27,522
| -77% | -$1.64M |
|
422
Charter Communications
CHTR
$17.2B
| $432K | 0.05% |
983
-323
| -25% | -$134K |
|
423
Deckers Outdoor
DECK
$13.6B
| $430K | 0.05% |
+5,022
| New | +$450K |
|
424
Edgewell Personal Care
EPC
$1.27B
| $429K | 0.05% |
+11,606
| New | +$448K |
|
425
Avery Dennison
AVY
$13.3B
| $428K | 0.05% |
+2,342
| New | +$424K |
|
Similar funds
PP
ECM
GCAC
CAM
D
GFS
FTIS
AIA
Seven Eight Capital's Q3 2023 Portfolio in Review
As of Q3 2023, Seven Eight Capital held 788 positions worth $855M, up 41% from $605M the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Seven Eight Capital deployed $327M of net new capital in Q3 2023, opening 316 new positions and adding to 155 existing holdings. Its largest new stake was Merck: 115,677 shares worth $11.9M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 22% a quarter earlier, followed by Consumer Discretionary and Healthcare.
On the sell side, the largest reduction was BioMarin Pharmaceuticals, an estimated $6.86M trimmed.
- Seven Eight Capital's largest Q3 2023 buy was Merck: 115,677 shares worth $11.9M.
- Seven Eight Capital added most to Edwards Lifesciences in Q3 2023, an estimated $13.6M increase.
- Seven Eight Capital's biggest Q3 2023 reduction was BioMarin Pharmaceuticals, cutting an estimated $6.86M.
- Seven Eight Capital fully exited Nasdaq in Q3 2023, selling an estimated $7.26M.
- Seven Eight Capital's ten largest holdings make up 13% of its $855M portfolio in Q3 2023.
- Seven Eight Capital opened 316 new positions and closed 211 in Q3 2023.
- Seven Eight Capital's portfolio value rose 41% quarter-over-quarter to $855M.
Based on Seven Eight Capital's 13F filing for Q3 2023, filed 14 Nov 2023.